GSA Capital Partners’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

GSA Capital Partners’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,751	Closed	-$31K	–	2003
2022 Q3	$31K	Sell	1,751 -6,264	-78%	-$134K	﹤0.01%	1440
2022 Q2	$178K	Buy	8,015 +4,453	+125%	+$99.3K	0.03%	1103
2022 Q1	$99K	Buy	3,562 +2,987	+519%	+$109K	0.01%	1294
2021 Q4	$26K	Buy	+575	New	+$38.7K	﹤0.01%	1355
2019 Q2	–	Sell	-734	Closed	-$123K	–	1809
2019 Q1	$123K	Sell	734 -45	-6%	-$6.71K	0.01%	1313
2018 Q4	$85K	Buy	+779	New	+$156K	0.01%	1235
2018 Q3	–	Sell	-79	Closed	-$170K	–	1977
2018 Q2	$170K	Hold	79	–	–	0.01%	1563
2018 Q1	$197K	Buy	+79	New	+$176K	0.01%	1475
2014 Q3	–	Sell	-17	Closed	-$32K	–	1974
2014 Q2	$32K	Buy	+17	New	+$33.6K	﹤0.01%	1764

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

GSA Capital Partners's ONCT Position: Q4 2022 in Review

GSA Capital Partners sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2022, closing a stake of 1,751 shares — an estimated $31K sold.

GSA Capital Partners first reported a position in ONCT in Q2 2014 and held it in 9 quarters. The position peaked at $197K in Q1 2018. 58 funds tracked by Wall St. Rank hold ONCT as of Q4 2022.

GSA Capital Partners reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
GSA Capital Partners sold 1,751 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $31K.
GSA Capital Partners first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2014 and held it in 9 quarters.
GSA Capital Partners's Oncternal Therapeutics, Inc. Common Stock position peaked at $197K in Q1 2018.
58 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.